Login to Your Account



NewCo News

Amarantus Restart Makes Another Run at MANF Protein

By Catherine Shaffer
Staff Writer

Friday, June 15, 2012
Amarantus Biosciences Inc. is an early stage biotech devoted to controlling diseases related to programmed cell death. Its lead program focuses on mesencephalic astrocyte-derived neurotrophic factor (MANF) as a therapeutic protein for conditions such as Parkinson's disease and traumatic brain injury.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription